Sk Biopharmaceuticals Co., Ltd. (326030)

Overview

SK Biopharmaceuticals Co., Ltd., established in 1993 and situated in Seongnam-si, South Korea, operates under the aegis of SK Inc. as its subsidiary. This pharmaceutical entity dedicates itself to the discovery and development of medicinal solutions, particularly targeting central nervous system disorders. By focusing on this specialty area, SK Biopharmaceuticals has positioned itself as a leading innovator in the development of treatments for a range of neurological conditions.

Products and Services

• Cenobamate

  An anti-seizure medication offered by the company, Cenobamate is developed for the management of epilepsy. This product underscores SK Biopharmaceuticals’ commitment to addressing the challenges faced by individuals living with seizure disorders.

• Solriamfetol

  This medication is a part of the company's portfolio aimed at improving wakefulness in individuals suffering from excessive daytime sleepiness. It highlights the firm's dedication to enhancing the quality of life for patients with sleep disorders.

• Carisbamate

  Currently in Phase 3 clinical trials, Carisbamate is being explored as a potential treatment for Lennox-Gastaut syndrome, a complex form of epilepsy marked by multiple types of seizures and intellectual disability.

• Relenopride

  In Phase 2 clinical trials, Relenopride represents the company’s efforts in addressing rare neurological diseases. This investigational drug exhibits the breadth of SK Biopharmaceuticals’ research endeavors.

• SKL24741

  This candidate is undergoing Phase 1 clinical trials for the treatment of epilepsy. It signifies the ongoing quest of the company to broaden its epilepsy management portfolio.

• SKL20540

  SKL20540 is another promising candidate from SK Biopharmaceuticals that is in Phase 1 clinical trials, aiming to offer new hope for individuals struggling with schizophrenia, a disorder that affects a person’s ability to think, feel, and behave clearly.

• SKL27969

  Targeting the treatment of advanced solid tumors, SKL27969 is in development, reflecting the company’s venture into oncology. This project aims to provide novel solutions for cancer patients, extending the firm's impact beyond neurological disorders.

• SKL13865

  With a focus on addressing Attention Deficit/Hyperactivity Disorder (ADHD), SKL13865 is under clinical trials. This investigational drug underscores the company's commitment to tackling a wide spectrum of central nervous system disorders.

• SKL-PSY

  SKL-PSY, which is in Phase 1 clinical trials, is aimed at the treatment of bipolar disorder. This initiative reflects the company’s dedication to providing therapeutic options for a broader range of psychiatric conditions.